Clinical Trial Update: NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating neoadjuvant therapy for resectable non-small cell lung cancer using a combination of NK-cell therapy, a PD-1 antibody, and pla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Natural Killer cell therapy (natural killer cell therapy)
• PD-1 antibody (PD-1 inhibitor)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Resectable Non-small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING